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Summary
Encephalitic syndromes are a common medical
emergency. The importance of early diagnosis and
appropriate treatment is paramount. If initial inves-
tigations for infectious agents prove negative, other
diagnoses must be considered promptly. Autoimmune
encephalitides are being increasingly recognized as
important (and potentially reversible) non-infectious
causes of an encephalitic syndrome. We describe
four patients with autoimmune encephalitis—
3 auto-antibody positive, 1 auto-antibody nega-
tive—treated during the last 18 months. A compre-
hensive review of the literature in this expanding
area will be of interest to the infectious diseases,
general medical and neurology community.
Introduction
Encephalitis (inflammation of the brain parenchyma)
is a common medical emergency. Failure to appro-
priately diagnose the correct aetiology of an enceph-
alitic syndrome can lead to significant morbidity and
mortality.
Of infectious agents, viruses cause a significant
proportion of encephalitis. Herpes simplex enceph-
alitis (HSE) is the most common viral encephalitis
with 2000 cases per year in the USA, the majority of
cases being HSV-1 infection in the young and
elderly.1
However, non-infectious aetiologies and, more
specifically, autoimmune phenomena are being in-
creasingly recognized as causes of encephalitis.2
A variety of autoimmune causes have now been
described including anti-LGI1 encephalitis (pre-
viously termed anti-voltage-gated potassium chan-
nel ‘‘anti-VGKC’’ antibody encephalitis) and anti-
N-methyl-D-aspartic acid receptor (anti-NMDAR)
encephalitis.3,4 It has been recognized that some
patients presenting with encephalitis show full re-
covery after treatment with steroids or immunomo-
dulatory therapy indicating an autoimmune cause
even in the absence of confirmatory serology.5,6
Despite a growing knowledge of autoimmune en-
cephalitis (AE), this area remains poorly understood.
Diagnosis is often considered late or not at all, re-
sulting in poor outcomes. Moreover, recent clinical
review articles giving an overview of viral enceph-
alitis omit recognized autoimmune causes such as
anti-NMDAR encephalitis in an otherwise compre-
hensive list of non-infective differential diagnoses.7
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The intention of this article is to raise awareness of
AE, a potentially reversible cause of a common med-
ical emergency. We present four illustrative cases of
AE to compare and contrast the variability of pres-
entations, aetiology, management and outcome.
Case 1
In June 2009, a 16-year-old student was admitted
with change in personality after an episode of loss
of consciousness (LOC). Three days prior to admis-
sion she had had an episode of depersonalization
and derealization with disorientation to place. It was
followed the same evening by a tonic–clonic seizure
at a graduation ball. She was seen in the emergency
department and discharged later that night. Over the
next 2 days, she exhibited bizarre behaviour with
inappropriate smiling, disinhibition, poor self-care,
altered sleep pattern and an episode of faecal incon-
tinence. There was no other relevant recent medical
history. Past medical history revealed anosmia since
birth of unknown origin. Family, medication, gynae-
cological and social history were unremarkable. A
full neurological examination was normal. MR brain
was normal. Cerebrospinal fluid (CSF) examination
showed 360 red cells/ml in a non-traumatic tap,
absent leucocytes, isolated oligoclonal bands with
normal protein and CSF:serum glucose ratio. She
was commenced on IV acyclovir and phenytoin.
Two days into her in-patient stay, she became very
agitated. Her behaviour fluctuated and at times she
was disorientated to place. An electroencephalo-
gram (EEG) showed excess of beta and pronounced
generalized delta waves compatible with a diffuse
encephalopathy. Lamotrigine was added to the anti-
epileptic medication and clarithromycin to cover
possible mycoplasma encephalitis. Auto-antibodies,
tumour markers and toxicology screen were nega-
tive, as was CSF virology. Repeat MR brain was
normal. Samples were sent for anti-NMDA receptor
antibodies, paraneoplastic (Anti-Hu, Anti-Yo, Anti-Ri,
Anti-Ma 1/2, Anti-CRMP-5 and Anti-Ampiphysin)
and VGKC antibodies.
The patient went on to develop episodes of hyper-
arousal over the next week with breath-holding
attacks, oro-facial movements (manifesting as
repetitive fish movements of the mouth) and pelvic
thrusting. She remained disorientated with intermit-
tent anxiety and poor memory. A repeat lumbar
puncture (LP) showed 20 white cells/ml of which
80% were lymphocytes. She had a 5-day course of
intravenous immunoglobulin (IVIG) at 0.4mg/kg/day
and methylprednisolone (MP) at 500mg/day; fol-
lowed by 60mg/day of oral prednisolone. A pelvic
USS and subsequent pelvic MRI were normal apart
from physiological ovarian cysts. Further follow-up
USS and MRI has shown resolution of the cysts with
no further abnormalities.
Over the next two weeks she showed a slow
improvement in alertness and orientation but con-
tinued to have disordered thoughts, occasionally ag-
gressive outbursts, echolalia, repetitive use of words
or people’s names and marked written verbigera-
tion. She also reported auditory hallucinations
which she defined as voices of her ‘family members
that were inside [her] head’. Quetiapine was added
to her medication and a second 5-day course of
IVIG given. Cognitive Assessment of Minnesota
(CAM) was carried out revealing poor memory and
concentration.
Five weeks into admission, anti-NMDA antibody
was reported as positive. She continued to improve
and phenytoin and prednisolone were weaned off.
Fluoxetine was added to medications due to on-
going mood lability. She began to be able to take
weekend leave and was discharged nearly 2 months
after admission.
By December 2009, 6 months post-admission
there had been complete resolution of her symptoms
and quetiapine and fluoxetine were also tapered off.
Case 2
A 26-year-old recruitment consultant was admitted
in May 2009 with confusion and altered behaviour.
His family described a single episode of LOC 3 weeks
prior to admission with no recollection of the event
and a Computed Tomography (CT) head at this time
was normal. Since then, he had become more with-
drawn and appeared paranoid. He complained of
transient inability to feel his legs and his family
noted episodes of shaking of limbs without LOC or
other features of seizure activity. These symptoms
progressed with further emotional lability, change
in personality, hallucinations and one other episode
of LOC.
On admission in May, he was disorientated, agi-
tated and confused. He had neither focal neurology
nor meningism at this time but a raised temperature
of 388C. CT brain scan was normal. An LP revealed
2 polymorphs/ml, 48 lymphocytes/ml, protein 0.58g/l
with a normal serum–CSF glucose ratio. Antibacterial
and antiviral treatments were initiated and haloperi-
dol and diazepam were escalated to control agita-
tion. It was noted that the patient had a raised
creatine kinase with mild renal impairment. A sub-
sequent MR brain scan and EEG were normal. HIV
antibody test was negative. Five days after admission
he was transferred to the Regional Infectious
Diseases unit.
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Neurological review revealed catatonic posturing,
globally increased tone with ankle clonus, unilateral
tremulousness and shaking, cogwheel rigidity and
no response to painful stimuli. A repeat LP yielded
similar results to the first. He was continued on anti-
virals and clarithromycin was added to treat the
possibility of mycoplasma encephalitis. He was
commenced on MP and immunoglobulin intraven-
ously. Anti-basal ganglia and anti-NMDA antibodies
were requested. An ultrasound of the testes was
normal as were tumour markers.
He continued with orofacial dyskinesias, insom-
nia, bland facies, catatonia and worsening visual
and auditory hallucinations. All CSF virological
tests returned negative including Mycobacterium tu-
berculosis PCR. However, after a month as an inpa-
tient, the patient continued to be extremely unwell
with severe ongoing symptomatology and lympho-
cytosis in the CSF. Therefore, due to these concern-
ing features, he was commenced on empirical TB
treatment, doxycycline and ceftriaxone for borrelio-
sis, and transferred to ITU for plasma exchange and
sedation. Two further LPs did not yield any new in-
formation and were negative for M. tuberculosis
PCR. The patient also received a further course of
IVIG and MP shortly after starting TB therapy.
Eleven days after commencing TB treatment, the
anti-NMDA antibodies result came back as strongly
positive and therefore TB treatment was stopped and
therapy with cyclophosphamide and rituximab was
started. He also started electroconvulsive therapy
(ECT) for catatonia. Over the next couple of
weeks, he improved and had more lucid episodes.
Then, 7 weeks after admission, mycobacterial cul-
ture on the initial CSF sample returned positive for
fully sensitive M. tuberculosis and anti-tuberculous
treatment was reinstated with the addition of ster-
oids. On revisiting history, no travel, exposure or
preceding clinical history (no headache, meningism,
cough, weight loss, night sweats or fever) suggested
either pulmonary or extra-pulmonary TB infection.
Over the next couple of months, his mental state
and catatonia improved and he was discharged on
anti-TB therapy after an inpatient stay of 18 weeks.
And 5 months after discharge he had returned fully
back to normal and was able to return to work.
Case 3
In April 2010, a 76-year-old lady with a past history
of diet-controlled type 2 diabetes was admitted to
her local hospital with a 2-week history of fluctuat-
ing confusion. She was uniformly afebrile. Routine
haematological and biochemical parameters were
normal, aside from mild hyponatraemia at Na
130mmol/l. While in hospital she suffered a short
lived generalized tonic–clonic seizure. She was not
orientated to time or place and her Glasgow Coma
Scale (GCS) varied between 7 and 14. She had a CT
head which was normal but an EEG showed slow
wave activity indicative of an encephalopathic pro-
cess. She was started on sodium valproate, cloba-
zam and prednisolone.
Over the next few days her GCS deteriorated to
3–4/15 and she was started on a phenytoin infusion
for suspected non-convulsive status epilepticus
(NCSE). Due to profound bradycardia and hypoten-
sion this was stopped. Levetiracetam was added to
her anti-epileptic regimen and the dose of sodium
valproate increased. She was transferred to the neur-
ology high dependency unit. While there she was
noted to be persistently hypothermic with tempera-
tures down to 338C but endocrinological investiga-
tions were normal. An MRI head showed high signal
changes in the hippocampal areas consistent with
the clinical diagnosis of limbic encephalitis (Figure
2). She was given 3 days of MP 1 g per day before
continuing on oral prednisolone at 50mg per day. A
further EEG showed NCSE and she was anaesthe-
tized. IVIG was given for a total of 5 days and
phenytoin was added to the anti-epileptic regimen.
One week into her admission, a repeat EEG showed
no epileptiform activity but diffuse slow waves inter-
mixed with small sharp waves seen over the left
frontotemporal region interrupted by periods of at-
tenuation of activity for 20–30 s. Over the next
week, her GCS remained 3–4, EEG continued to
show encephalopathic features and she was trans-
ferred to the ward. By day 20, there were signs of
some improvement. She was given a second cycle
of MP and IVIG. On day 26, anti-VGKC antibodies
were reported as strongly positive [herein to be
referred to as anti-LGI1(Leucine-rich glioma inacti-
vate 1) antibodies, see discussion]. GCS improved to
8 and prednisolone was continued orally. She re-
mained stable but was treated with antibiotics and
physiotherapy for ventilator-associated pneumonia.
Prednisolone began to be tapered 7 weeks into ad-
mission. She remained in a state of low arousal, was
transferred to a specialist nursing home but died
10 months after her initial presentation.
Case 4
In October 2009, a previously fit and well 30-year-old
male, presented with a 3-week history of headaches,
confusion, sleep disturbance, personality change
and a partial complex seizure. He had had a flu-like
illness 4 weeks earlier treated with oseltamivir
(Tamiflu). Initial CT and MR brain scans
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were normal but 2 LPs revealed CSF lymphocytosis
(400/ml and 63/ml, respectively) with normal protein,
glucose, virological screen and negative culture.
Early therapeutic management included sedation
with haloperidol, lorazepam and olanzapine; intra-
venous cefotaxime, aciclovir and clarithromycin;
and sodium valproate.
After 4 days, he was transferred to the Regional
Infectious Diseases unit. He remained confused and
agitated requiring high amounts of sedation.
Medication was rationalized to diazepam and que-
tiapine after a psychiatric review. He suffered a
tonic–clonic seizure and temporarily dropped his
GCS score to 3/15. He was soon noted to be cata-
tonic. His GCS spontaneously improved to 13/15
and a neurology review revealed rigidity and the
pillow sign consistent with catalepsy (the ‘‘psycho-
logical pillow’’ describes a postural state in which
the patient maintains—sometimes for long periods—
a posture with head a few inches off the bed if the
pillow is removed). He continued on antimicrobial
therapy and an auto-immune screen and paraneo-
plastic (Anti-Hu, Anti-Yo, Anti-Ri, Anti-Ma 1/2, Anti-
CRMP-5 and Anti-Ampiphysin) screen were
requested.
A 3rd LP was performed which showed a
persistently raised but improving lymphocyte count
at 18/ml. EEG and MR brain were also normal. A
bilateral ptosis was noted on day 8 and he was
started on MP (1 g per day for 3 days). He improved
dramatically over the next couple of days with
reduced catatonia and increased communication.
His reaction time continued to be delayed and his
parkinsonian tremor remained. He was continued
on oral prednisolone at 60mg per day. All blood
and CSF viral polymerase chain reaction (PCR)
tests were negative as were an HIV antibody test,
Hepatitis B and C screen, atypical pneumonia ser-
ology, serum ACE, autoimmune screen, treponemal
and borrelia serology, anti-NMDA, anti-basal gang-
lia, anti-LGI1 and paraneoplastic antibodies.
Over the next 2 weeks, he was weaned off seda-
tives and his sleep-cycle, agitation and communica-
tion all improved. A neurological exam at this time
showed a mild bilateral ptosis and intention tremor.
He was discharged after a month’s inpatient stay
weaning off oral prednisolone. When seen in outpa-
tient clinic, he was well with complete resolution of
symptoms apart from mild short-term memory loss.
Discussion
Patients presenting with an encephalitic syndrome
represent a diagnostic challenge. Estimated inci-
dence of viral encephalitis in the UK, based on
hospitalized patients from 1989 to 1998, was ap-
proximately 1.5 per 100 000 overall.8 More recent
estimates (from the northwest of England) of admis-
sion rates with encephalitic syndrome were higher
at approximately 2.9 per 100 000.9 Incidence is
higher in specific patient groups such as the young
and elderly. It is of note that a large review of over
1500 patients presenting with encephalitis to health-
care facilities in California, USA, showed that only
16% had a confirmed aetiological agent (the major-
ity of these viral followed by bacterial); 13% had a
suspected aetiological agent; and 8% had a non-
infectious cause identified (autoimmune disease and
vasculitis being the most common). Aetiology was
not found in nearly two-thirds of cases referred to
specialist units.10 This highlights the importance of
considering AE early in situations where no clear
infectious aetiology has been identified.
Autoimmune conditions are not a common cause
of encephalitis. However, with recognition of newer
antibodies, diagnostic serology is becoming increas-
ingly available. The above cases, encountered
within an 18-month period, illustrate the spectrum
of presentations of varying types of AE. Cases 1 and
2 describe two young patients with anti-NMDAR
encephalitis, Case 3 describes an elderly lady with
anti-LGI1 encephalitis. Case 4 describes a patient
with non-infectious, presumed AE that responded
well to immunomodulatory therapies (the patient
was left with only mild short-term memory loss) al-
though no autoimmune antibody was identified.
It is important to note the relevant signs, symp-
toms and investigations that may guide the clinician
to a positive diagnosis of AE. These features are
highlighted in Table 1. In addition to augmenting
our understanding of the presentations of these ill-
nesses, these cases also highlight the need for ag-
gressive, early and appropriate treatment of patients
with AE to achieve good outcomes. It is a disease
process that if considered early, diagnosed promptly
and treated appropriately (including aggressive treat-
ment with therapies such as high-dose steroids,
IVIG, plasma exchange, rituximab and cyclophos-
phamide) can be reversed and the patient restored
to their premorbid state.
Initial investigation in an encephalitic patient
would commonly include CT of the brain with con-
trast, LP with cell count, protein, glucose (and serum
glucose), viral screen, acid-alcohol fast bacilli
(AAFB) smear, bacterial and mycobacterial culture.
An MR brain is mandatory and an EEG may also be
performed depending on the clinical situation. Some
of the results from these investigations in both the
case of infection and AE may overlap. However, it
is imperative that a diagnosis of AE be considered by
treating physicians when other more common
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causes have been excluded or when there are cer-
tain diagnostic indicators for AE, as described below.
Figure 1 shows a clinical algorithm for the diagnosis
of AE.
Anti-NMDAR encephalitis has only recently been
described, often occurring in female patients with
associated ovarian teratomas, however, men are af-
fected in 30% of cases.11,12 Of note, a significant
(40%) proportion of anti-NMDAR encephalitis is
found in children.4 A recent study from the US
found the rates of anti-NMDAR antibodies in en-
cephalitic patients admitted to ITU to be 1%;13 in
the UK a prospective multicentre study showed 4%
of all encephalitic patients had anti-NMDAR en-
cephalitis.14 The NR1 subunit is the target antigen
for NMDA receptor antibodies (NMDAR). NR1 is
down-regulated by selective and reversible decrease
in NMDAR surface density and synaptic localization
that correlates with patients’ antibody titres.15 This
causes reduction in GABA release from pre-synaptic
neurons that subsequently results in increased
glutamate release, dopamine dysregulation and
excitotoxicity leading to classical anti-NMDAR
encephalitis features.16
A prodromal syndrome involving headache, low
grade fever and non-specific viral illness (nausea,
vomiting, upper respiratory tract symptoms) up to
2 weeks prior to presentation—commonly with psy-
chiatric symptoms—is found in about 70%.2,12 Due
to the prominence of psychotic symptoms, patients
Figure 1. Clinical algorithm for diagonsis of AE.
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may initially be admitted under psychiatric care.
Early features of anti-NMDAR encephalitis include
psychosis (frequently involving anxiety, paranoia,
sleep disturbance, grandiose delusions and mania),
speech and language problems on a varying spec-
trum of echolalia (see Patient 1) to mutism, and
memory problems which are often under-estimated
amidst the psychiatric and language problems.2,12
After this initial phase there is rapidly progressive
neurological disturbance. This can include motor
or complex seizures, decreasing responsiveness,
dyskinesias and autonomic instability. Among the
varied dyskinesiae that can occur there is a promin-
ence of oro-lingual-facial movements (see ‘fish-
mouthing’ Patient 1). Other dyskinesias noted in
Dalmau et al.’s2,12 cohort include limb and trunk
choreoathetosis, elaborate leg and arm motions,
dystonia, rigidity, opisthotonus and oculogyric
crises; these may be simultaneous or alter through
the illness. Autonomic instability may be prominent
causing haemodynamic and respiratory instability,
in rare cases causing bradycardia requiring
temporary pacemaker insertion.17 In addition cen-
trally-originated hypoventilation may require ITU
admission as occurred in Case 3.2,4 Reports of
rarer neurological presentations including opsoclo-
nus–myoclonus syndrome at presentation are also
documented.18
Case 1 had no specific prodromal period but pre-
sented with a variety of relevant neurological fea-
tures including seizures, disinhibition and psychosis.
Case 2, in contrast, had an episode of LOC—pos-
sibly a seizure—1 month preceding presentation,
with personality changes and emotional lability in
the interim. Both patients had distinct signs compat-
ible with anti-NMDA encephalitis including sleep
disturbance, seizures, behavioural disturbances
and movement disorders. Our patients had promin-
ent movement disorders including orofacial dyskin-
esia in both cases and catatonia in Case 2; and
visual and auditory hallucinations. Case 2 had initial
hyperthermia during admission: a series of female
children with AE in Japan described hyperthermia
as a presenting feature in 90%;19 consequently,
hyperthermia does not exclude AE. A further differ-
ing feature between the presentation of adults and
children is a lower frequency and severity of hypo-
ventilation (as seen in Case 1 who also exhibited
breath-holding attacks) and more autonomic in-
stability in children.4
A patient with anti-NMDAR encephalitis may
have abnormalities of both CSF and MRI. 80% of
patients with confirmed anti-NMDAR encephalitis
have abnormal CSF with the majority of these ex-
hibiting a lymphocytic pleocytosis but over half also
showing raised protein; there may also be the
presence of isolated oligoclonal bands in the CSF
of patients with AE (around 60%12) as found in
Case 1’s initial sample. Most patients have intra-
thecal production of anti-NMDAR antibody and in
a recent article relating to over 400 patients with
anti-NMDAR encephalitis, none were shown to
have anti-NMDAR antibodies in serum alone.20
Anti-NMDA antibodies can be detected in both
the serum and CSF; levels may be monitored.17
Patients who respond to treatment (discussed
below) have lower levels of anti-NMDA antibodies
post- than pre-treatment whereas those with poor or
no response to treatment may have persistently high
antibody levels.2,12,15
With regards to brain MRI, this is unremarkable in
50%. In the remaining 50%, T2 or FLAIR signal
hyperintensity might be seen in the hippocampi,
cerebellar or cerebral cortex, frontobasal and insular
regions, basal ganglia and brainstem.12 These signal
changes may only be transient however and were
not seen to significantly correlate with the patients’
clinical neurological features. Over three quarters of
patients had abnormal EEGs, predominantly with
generalized or frontotemporal slow or disorganized
(delta–theta) activity in the absence of epileptic dis-
charges.4 In Case 1, the patient had a normal MRI
brain but EEG showed an excess of beta and pro-
nounced generalized delta waves compatible with a
diffuse encephalopathy and LP revealed a CSF lym-
phocytosis with elevated protein. Case 2 had similar
CSF abnormalities but a normal EEG and MR brain
scan. Both patients had high levels of anti-NMDA
antibodies. As described, the CSF of Case 2 did later
growM. tuberculosis in the sample obtained prior to
institution of any immunosuppressive intervention
(including steroids). This suggests that coexistent
TB infection may have been a trigger to autoimmune
anti-NMDA encephalitis. The illness and clinical
syndrome were predominantly due to anti-NMDA
encephalitis, which responded appropriately to ster-
oids, cyclophosphamide, rituximab and plasma ex-
change. The growth of M. tuberculosis in an
encephalitic patient of course necessitated anti-TB
treatment. However, the clinical presentation and
response to treatment in this case clearly highlights
the need to analyse the clinical syndrome astutely
and not be wholly reliant on investigative results in
isolation.
Recent papers have described the histopathology
of brain and neuronal tissue in relation to auto-
immune encephalitides.20 The authors review
studies of the cellular and synaptic effects of these
antibodies in hippocampal neurons in vitro and pre-
liminary work in rodent models. Moscato et al.20
found that in the anti-NMDAR brain biopsies there
was a rarity of T cell infiltrates as opposed to that
Autoimmune encephalitis 927
by guest on O
ctober 19, 2016
D
ow
nloaded from
 
found in paraneoplastic syndromes in which T cells
are predominant.21 What also remains to be under-
stood, is why the disease preferentially affects hip-
pocampal NR1 subunits, when these can be found
throughout the brain. Overall histological examin-
ation of brain biopsy have not shown any changes
specific to anti-NMDAR encephalitis with the ma-
jority of the few samples taken in this setting show-
ing mainly perivascular lymphocytic cuffing.
Around 70% of the teratomas found in females
with anti-NMDA encephalitis may be benign. If
such a tumour is found, immunotherapy and re-
moval have been associated with a better outcome
than without removal or treatment.22–24 It must be
remembered however, that about 40% of patients in
other patients series reported had no associated
tumour found.2,12
Immunotherapy with IVIG and high-dose ster-
oids—intravenously initially—has been shown to
improve outcome but may be associated with re-
lapse especially without tumour removal.2,17 Case
1 was slow to respond to these treatments, thus a
second course was prescribed. Imaging did not
reveal an associated tumour. Both Cases 1 and 2
needed repeated courses of MP and IVIG because
of poor responses to the initial treatment cycle. Of
note, both responded well to the second course of
IVIG and MP but, in addition, Case 2 also received
cyclophosphamide and rituximab with adjunctive
ECT and plasma exchange. Both patients made a
full recovery.
Although previously termed ‘anti-VGKC enceph-
alitis’, recent evidence suggests that it is actually
another autoantigen—LGI1—that is associated
with limbic encephalitis and this terminology will
be used throughout.25 In addition, other studies sug-
gest that another auto-antigen contactin-associated
protein-like 2 ‘CASPR2’ (expressed in hippocampal
neurons) is associated with illnesses previously
attributed to anti-VGKC antibodies such as drug-
refractory epilepsy, encephalitis, peripheral nerve
dysfunction or a combination of both: Morvan syn-
drome or neuromyotonia.26–29 LGI1 is a secreted
neuronal protein that functions as a ligand for two
epilepsy-related proteins ADAM22 and ADAM23.30
As opposed to the previous supposed anti-VGKC
mechanism of action, anti-LGI1 does not encode
structural components of ion channels. It is specu-
lated that antibody-mediated disruption of LGI1
function causes increased excitability, which may
result in seizures or encephalopathy. Case 3 de-
scribes an elderly female with anti-LGI1 limbic en-
cephalitis that responded poorly to immunotherapy
with IVIG and MP. It must be noted that at the time
of investigation the LGI1 antibodies were not being
characterized in our reference laboratory’s studies.
Therefore, the results only specified VGKC antibo-
dies and the sample was since discarded. The clin-
ical profile of this patient, however, best fits
anti-LGI1 encephalitis and will be discussed as
such below.
The limbic system encompasses the amygdala,
hippocampus and hypothalamus and—among
other functions—is responsible for memory and
emotion. Limbic encephalitis was first described in
patients with severe short-term memory impairment
or dementia in association with bronchial carcin-
oma.31 There has been increasing clinical and
neuro-imaging recognition of this condition in the
past decade. Cardinal symptoms of LE—and there-
fore LGI1 encephalitis—are severe short-term
memory impairment with psychiatric symptoms
such as personality change, depression, anxiety, hal-
lucinations, confusion and complex partial—often
temporal or classically in LGI1 encephalitis facio-
brachial tonic seizures32—and generalized seiz-
ures.33,34 Another prominent symptom, found in
40% of patients is myoclonus—also strongly ex-
hibited in mice lacking LGI1.25 Of note, symptoms
are similar for CASPR2 syndromes but additionally
may include peripheral nerve hyperexcitability and
axonal sensorimotor neuropathy.28 Our patient ex-
hibited confusion, change in conscious level and
seizures. In addition, as has previously been
described in patients with anti-LGI1 encephalitis,
she had autonomic instability with labile tempera-
ture and blood pressure.
Neuroimaging by MRI shows unilateral or bilat-
eral, asymmetrical, high-signal changes in mesial
temporal lobes (Figure 2) that enhance on T2-
weighted scans (up to 84% of patients).5,25 High-
signal changes in the hippocampal area were seen
in our patient. CSF, as for anti-NMDA encephalitis,
may show a pleocytosis with a lymphocytic pre-
dominance, raised protein and oligoclonal bands.35
Hyponatraemia, as in our patient, is common, oc-
curring in over half of patients both those with
underlying carcinoma and those without; this is
thought to be mediated by LGI1 expression in
the hypothalamus and kidney and averaged Na
128mmol/l in Lai’s review.25,36 EEG is often abnor-
mal showing focal or generalized epileptic dis-
charges or—as in Case 3—slow wave activity.37
In contrast to Anti-NMDAR encephalitis, asso-
ciated underlying tumours are only found in 11%
of patients in Anti-LGI1 encephalitis;25 in those
who do have a tumour, the encephalitis can precede
the identification of the neoplasm in up to three
quarters of patients.34,38,39
A thorough search, initially for an infectious aeti-
ology and then for exclusion of underlying malig-
nancy (tumour should be removed if found) should
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be undertaken. For anti-NMDA encephalitis, the
treatment is immunotherapy with high-dose steroids
and IVIG with other agents such as cyclophospha-
mide, rituximab or plasma exchange being used as a
second line2. When found in the CSF or serum,
anti-LGI1 antibodies are associated with a better re-
sponse to treatment than those treated for presumed
auto-immune encephalitis without presence of
auto-antibodies.3 After treatment, a quarter of pa-
tients will have full recovery and one half will be
left with only mild disability.25 The neurological def-
icits may be subtle and difficult to elicit, however,
and in some cases are sufficient to preclude a return
to work.
Our patient (Case 3) had poor response to two
courses of immunotherapy despite anti-LGI1 antibo-
dies being present and no underlying tumour being
found. Her advanced age, prolonged stay on ITU
and ventilator-associated pneumonia (VAP), may
have negatively influenced her response to treat-
ment. It may also be postulated that treatment was
not started until approximately 3 weeks after admis-
sion and 5 weeks into her illness. Moreover, despite
the poor response to the above treatments, due to
the patient’s poor general condition, plasma ex-
change or other immunotherapy could not be
initiated.
Case 4 describes a case in which the young male
patient presented with features of AE with diffuse
brain involvement following a prodromal influenza-
like illness a few weeks previously. He had a CSF
lymphocytic pleocytosis but his EEG and MRI head
were normal. He had profound catatonia and
parkinsonism. No infectious, auto-immune or para-
neoplastic aetiology was identified on testing of
serum and CSF. There are further cases in the litera-
ture reporting patients presenting with features of LE,
negative anti-LGI1 and anti-NMDA antibodies but
full response to immunotherapy with IVIG and ster-
oids.40 These cases did note, however, EEG and MRI
changes—EEG showed bitemporal slowing and par-
oxysmal slow wave bursts; MRI showed bilateral
swelling in the medial temporal lobes. Our patient
responded profoundly to immunotherapy—a re-
sponse which was maintained—indicating a likely
autoimmune cause for the encephalitis. It must be
noted that there are other conditions which can
cause AE in addition to anti-NMDAR, anti-LGI1or
CASPR2; our patient may have had one of these
but this was not identified. Such disorders included
Anti-AMPA, Anti-GABA and the intracellular anti-
gens anti-Hu and anti-Ma2.
AMPA receptor antibodies (Glutamate
Receptors—GluR1/2) is one of the autoimmune
causes of limbic encephalitis. Glutamate is on of
the main excitatory neurotransmitters with GluR1/2
being the predominant AMPA subtype in the hippo-
campus (GluR3 is associated with the distinct dis-
order, ‘Rasmussen’s syndrome’). Like Anti-NMDAR
encephalitis, Anti-AMPA receptor encephalitis is
associated with tumours in females and good re-
sponse to immunotherapy.29,41,42
Anti-GABA AE is caused by disruption of the
metabotropic Anti-GABA beta receptor. When dis-
rupted, this receptor causes limbic encephalitis with
prominent seizures and memory dysfunction.43 The
patients in Lancaster et al.’s case series (average age
62 and roughly equal sex distribution) all presented
with early and prominent seizures; EEG and MRI
findings were consistent with predominant limbic
dysfunction. Around 47% of patients had small
cell lung cancer. Neurological improvement
occurred in 60% of the patients and was correlated
with prompt immunotherapy and tumour control.44
Paraneoplastic limbic encephalitides (PLE) are
predominantly related to Anti-Hu and anti-Ma2 anti-
bodies. Diagnosis is either by neuropathological
examination or the presence of following 4 criteria:
compatible clinical picture; interval of <4 years be-
tween neuro- symptoms and tumour identification;
exclusion of other neuro-oncological complications;
at least one of following—CSF with inflammatory
changes but negative cytology, MRI showing tem-
poral lobe abnormalities; EEG showing temporal
activity in the temporal lobes.29 Around 60% of pa-
tients in a series34 had antineuronal antibodies.
Only 57% had limbic changes on the MRI.
Patients with Anti-Ma 2 encephalitis were generally
young men with testicular tumours (as opposed to
Figure 2. MRI FLAIR sequence coronal view of Case 3
showing bilateral high-signal changes in mesial temporal
lobes and insular cortices.
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lung cancer as most common associated malig-
nancy in anti-Hu), hypothalamic involvement and
poor neurological outcome. Tumour treatment has
generally been shown to have a superior outcome
than immunomodulatory therapy in these cases.29
It is postulated that in the case of neoplastic-
associated AE, the presence of a tumour expressing
the specific autoimmune receptors breaks through
immune control and, essentially, produces the spe-
cific symptomatic syndromes. Another mechanism
may well cause this breakthough however, in
much the same way as Guillain–Barre Syndrome
occurs post-Campylobacter infection and
Sydenham’s Chorea post—Streptococcal infection.44
Overall, a combination of history, clinical, EEG
and CSF findings can point to a diagnosis of AE
even in the absence of positive auto-antibodies
(see Figure 1).
Conclusion
Although AE can present in a similar way to other
encephalitic processes—such as those of an infec-
tious aetiology—the cases described illustrate that
diseases such as anti-NMDAR, anti-LGI1 and other
AE may exhibit some distinct characteristic features.
The physician treating encephalitic patients, in
whom aetiology has not been confirmed, be their
speciality neurology, infectious diseases or general
medicine, must be vigilant to the possible diagnoses
of AE. The excellent response to treatment in three
out of four of our patients also reiterates the need for
prompt consideration, investigation and recognition
of AE. Treatment should be early and aggressive,
initially with steroids but also with addition of
IVIG, plasma exchange and—in refractory cases—
other immunotherapy such as cyclophosphamide
and rituximab. This appropriate and timely manage-
ment is likely to improve the outcome of AE, a con-
dition that—in many cases—may be wholly
reversible.
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